

Non-profit Org.  
U.S. Postage  
PAID  
Durham, NC  
Permit No. 60



## Commercial Support Acknowledgment

A complete list of supporters will be provided to attendees during the event.

## Target Audience

This educational program is directed toward Oncologists, Hematologists, Pharmacists, Pharmacy Technicians, Nurse Practitioners, Physician Assistants, Fellows, Nurses and other health care professionals interested in the treatment of patients with hematologic malignancies.

## Purpose

The purpose of this conference is to educate oncologists, hematologists, and the healthcare team regarding evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies. Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, traditional lecture and tumor board.

## Disclaimer

The information provided at this live activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

## Joint Accreditation Statement



In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.



JOINT ACCREDITATION  
INTERPROFESSIONAL CONTINUING EDUCATION

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 12.5 MOC points [and patient safety MOC credit] in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## Credit Statement

**Physicians:** Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of *12.5 AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Nursing:** Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 12.5 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

**Pharmacists:** Duke University Health System Department of Clinical Education and Professional Development designates this activity for 12.5 ACPE credit hours. Universal Activity Numbers: 0851-0000-17-014-L01-P & 0851-0000-17-014-L01-T.

## Special Needs Statement

The Duke Cancer Network is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.

PRESENTED BY THE DUKE CANCER NETWORK  
IN COLLABORATION WITH THE DUKE CANCER INSTITUTE

# DUKE DEBATES:

## Controversies in the Management of Patients with Hematologic Malignancies

April 21-23, 2017

Omni Grove Park Inn • Asheville, NC



**Duke** Cancer Institute



AGENDA



FRIDAY, APRIL 21, 2017

2:30pm

Registration

Advanced Practice Providers: Side Effect Management and Dose Modification Strategies for Targeted Therapies

Moderator: Heather Paradis, MSN, ANP

3:00pm

Welcome and Introductions

3:05pm

Integrating Cytogenetics and Molecular Data for AML Risk Stratification

Donna Adams, MSN, ANP

3:35pm

Managing Patients Post CAR-T Infusion

Anne Beaven, MD

4:05pm

Cardio-Oncology Toxicities and Management

Michael Khouri, MD

4:45pm

VTE Risk and Management in Hematologic Malignancies

Meredith Moorman, PharmD

New Avenues in Stem Cell Therapy and Hematopathology

Moderator: David Rizzieri, MD

3:00pm

The New WHO...What's Changing in the Classification Schema

Anand Lagoo, MD, PhD

3:30pm

Application of 'Next Gen Sequencing' Chips for Those with Hematologic Malignancies

Chad McCall, MD, PhD

4:00pm

BMT Update: 'In Home' Transplant - Bringing the Fight to Your Door

Anthony Sung, MD

4:45pm

Breakthrough Report: High Dose Therapy for Autoimmune Diseases Improves Survival

Keith Sullivan, MD

5:30–7:00pm

RECEPTION

SATURDAY, APRIL 22, 2017

7:00–7:45am

Registration and Breakfast

Immunotherapy Highlights

Moderator: Joseph O. Moore, MD

7:50am

Welcome and Pre-Session Survey

8:00am

Micro Transplantation for Elderly Patients with AML

Anthony Sung, MD

8:30am

Application of PD1 Inhibitors in Hematologic Malignancies

Anas Younes, MD (MSKCC)

9:10am

Debate: The Best Immunotherapy for ALL: BITE vs CAR-T

Anjali Advani, MD (Cleveland Clinic) vs. David Porter, MD (University of Pennsylvania)

9:55am

Break

Leukemia Highlights

Moderator: David Rizzieri, MD

10:10am

Pre-Session Survey

10:15am

Debate: We Can Cure CLL with Current / Soon to be Approved Agents

Anthony Mato, MD, MSCE (University of Pennsylvania) vs. Danielle Brander, MD

10:55am

Debate: All Patients with FLT3 + AML Should Receive Midostaurin Based Induction Therapy

Richard Stone, MD (DFCI) vs. Harry Erba, MD (University of Alabama)

11:35am

Leukemia Tumor Board with ARS

Drs. Rizzieri, Advani, Erba and Stone

12:05–1:05pm

Lunch and Time with Exhibitors

Lymphoma and Benign Hematologic Highlights

Moderator: Ara Metjian, MD

1:05pm

Pre-Session Survey

1:15pm

Debate: Genomics for all DLBCL is Not as Useful as we Thought...OR IS IT?

Anne Beaven, MD vs. Matthew McKinney, MD

1:55pm

Debate: Combined Modality Chemo-RT Should be the Standard Treatment for Stage I – II FL

Chris Kelsey, MD vs. Anas Younes, MD (MSKCC)

2:40pm

IV vs. Oral Iron

JJ Strouse, MD vs. Marilyn Telen, MD

3:20pm

Interactive Case Vignette

Direct Oral Anti-Coagulants vs. Warfarin for Anti-Phospholipid Antibody Syndrome

Ara Metjian, MD

4:00pm

Adjourn For the Day

SUNDAY, APRIL 23, 2017

7:00–7:45am

Registration and Breakfast

Highlights of CML and PMF Management and Lymphoma Tumor Board

Moderator: Louis Diehl, MD

7:50am

Pre-Session Survey

8:00am

Stopping TKI's in CML – Are we There Yet?

Joseph O. Moore, MD

8:30am

Debate: Mutation Status in PMF Should Guide Therapy

Lindsay Rein, MD vs. Brady Stein, MD (Northwestern)

9:15am

Lymphoma Tumor Board with Audience Response

Moderator: Louis Diehl, MD

Expert Panel Members: Drs. Beaven, McKinney and Younes

10:45am

Post Session Survey and Q&A

11:00am

Adjourn

Omni Grove Park Inn

290 MACON AVENUE • ASHEVILLE, NC 28804

TELEPHONE: 1.800.438.5800 • FAX: 1.828.210.8314

REFERENCE:

Group Number: **042017DUKEDEBAT**

WEBSITE:

**www.omnihotels.com/bookyourstay**

PER NIGHT ROOM RATES:

Single or Double Occupancy

\$299.00 per room

Please add \$40.00 for each third

and fourth person sharing a room

Check in time is after 4:00 pm

Check out time before 11:00 am

Please make reservations by

**Monday, March 20, 2017**

Register on line at **https://goo.gl/kSLNbl**

REGISTRATION FEE:

Physician ..... \$200.00

Fellow, Nurse, PA

and Pharmacist ..... \$150.00

Industry (not covered by grant

or exhibit fee)..... \$750.00

CANCELLATION POLICY:

The registration fee will not be refunded if

cancelled after **April 13, 2017.**

CONTACT/QUESTIONS:

For questions, please contact:

**Beth Tanner**

Duke Cancer Network

919.681.9869

e-mail: beth.tanner@duke.edu